5-甲基吡咯-2-羧酸 | 3757-53-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 5-甲基吡咯-2-羧酸
• 中文别名: 5-甲基-1H-吡咯-2-甲酸；5-甲基吡咯-2-甲酸
• 英文名称: 5-methyl-1H-pyrrole-2-carboxylic acid
• 英文别名: 5-methylpyrrole-2-carboxylic acid；5-Methylpyrrol-2-carbonsaeure；5-methyl-pyrrole-2-carboxylic acid；5-Methyl-pyrrol-2-carbonsaeure；4-methyl-pyrrole-2-carboxylic acid
• CAS: 3757-53-7
• 化学式: C₆H₇NO₂
• mdl: MFCD03011381
• 分子量: 125.127
• InChiKey: UFYABCWJPZTWHA-UHFFFAOYSA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  326.3±22.0 °C(Predicted)
• 密度：
  1.295±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methyl-1h-pyrrole-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methyl-1h-pyrrole-2-carboxylic acid
CAS number: 3757-53-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7NO2
Molecular weight: 125.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基吡咯-2-羧酸 在 三丁基膦 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 72.0h， 生成 [(3R,4S,5R,6R)-6-(4-benzhydryloxy-8-methyl-2-oxochromen-7-yl)oxy-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  香豆素A 1的合成

  摘要：

  简洁地合成了从链霉菌中分离得到的天然产物抗生素coumermycin A 1。在关键步骤中，通过与丙酮的糖基转移反应从新霉素制备了选择性保护的新糖。

  DOI：

  10.1016/s0040-4039(02)02487-5
• 作为产物：
  描述：

  山梨酸甲酯 在 氢氧化钾 、 lithium 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 5-甲基吡咯-2-羧酸
  参考文献：
  名称：

  Photochemistry of 3,6-dihydro-1,2-oxazines: A versatile route to substituted pyrroles

  摘要：

  DOI：

  10.1016/s0040-4039(00)87095-1

文献信息

• NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
  申请人：Calvet James P.

  公开号：US20110082098A1

  公开（公告）日：2011-04-07

  Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.

  新比奴霉素类似物在治疗、抑制和/或预防自体显性多囊肾病（ADPKD）中的囊肿形成方法中是有用的。本公开提供了治疗ADPKD的方法，包括给予香豆素-3-羧酰胺新比奴霉素类似物的治疗有效量。因此，该方法可以包括给予新比奴霉素类似物的治疗有效量，以降低mTOR途径磷酸化蛋白P-mTOR、P-Akt和P-S6K的水平，或其组合。此外，该方法可以包括给予新比奴霉素类似物的治疗有效量，以降低Hsp-90客体蛋白CFTR、ErbB2、c-Raf和Cdk4的水平，或其组合。
• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252859A1

  公开（公告）日：2021-12-16

  The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

  本公开提供了至少一种化合物、重氢化衍生物或药用可接受的盐，选自公式(I)化合物、其重氢化衍生物以及任何前述物质的药用可接受的盐，包含同一的组成物，以及制造和使用同一的方法，包括用于治疗APOL1介导的肾脏疾病。
• Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors
  作者：G.M. Kamal B. Gunaherath、Marilyn T. Marron、E.M. Kithsiri Wijeratne、Luke Whitesell、A.A. Leslie Gunatilaka

  DOI：10.1016/j.bmc.2013.06.042

  日期：2013.9

  inhibitory activity, inhibits Heat shock protein 90 (HSP90) by binding weakly to a putative ATP-binding site within its C-terminus. To develop more potent HSP90 inhibitors that target this site and to define structure–activity relationships (SARs) for this class of compounds, we have synthesized twenty seven 3-amido-7-noviosylcoumarin analogues starting from NB and CA. These were evaluated for evidence of

  最近的研究表明，新霉素（NB）是具有证明的DNA回旋酶抑制作用的古默霉素（CA）家族的一种抗生素，通过与C-内的一个假定的ATP结合位点弱结合来抑制热休克蛋白90（HSP90）。总站。为了开发靶向该位点的更有效的HSP90抑制剂并定义此类化合物的结构-活性关系（SAR），我们合成了27种从NB和CA开始的3-amido-7-noviosylcoumarin类似物。使用几种生物学测定法评估了这些物质对HSP90抑制的证据，包括抑制细胞增殖和细胞周期阻滞，诱导热休克反应，抑制体外萤光素酶重新折叠以及消耗HSP90客户蛋白c-erbB-2 /。 HER-2 / neu（HER2）。这项SAR研究表明，通过除去NB / C-3上的吲哚-2-甲酰胺基团取代C-3上的4-羟基-异戊基苯甲酰胺基，可以显着提高生物活性。组从香豆素环。如化合物所示，香豆素部分中的4-羟基甲基化可适度提高生物活性11和13。
• Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors
  作者：Matthew A. Jones、James D. Morton、James M. Coxon、Stephen B. McNabb、Hannah Y.-Y. Lee、Steven G. Aitken、Janna M. Mehrtens、Lucinda J.G. Robertson、Axel T. Neffe、Shigeru Miyamoto、Roy Bickerstaffe、Karl Gately、Jacqueline M. Wood、Andrew D. Abell

  DOI：10.1016/j.bmc.2008.05.048

  日期：2008.7

  A series of N-heterocyclic dipeptide aldehydes 4-13 have been synthesised and evaluated as inhibitors of ovine calpain 1 (o-CAPN1) and ovine calpain 2 (o-CAPN2). 5-Formyl-pyrrole 9 (IC(50) values of 290 and 25nM against o-CAPN1 and o-CAPN2, respectively) was the most potent and selective o-CAPN2 inhibitor, displaying >11-fold selectivity. The amino acid sequences of o-CAPN1 and o-CAPN2 have been determined

  已经合成了一系列的N-杂环二肽醛4-13，并作为绵羊钙蛋白酶1（o-CAPN1）和绵羊钙蛋白酶2（o-CAPN2）的抑制剂进行了评估。5-甲酰基-吡咯9（对o-CAPN1和o-CAPN2的IC（50）值分别为290和25nM）是最有效和最具选择性的o-CAPN2抑制剂，显示出> 11倍的选择性。已经确定了o-CAPN1和o-CAPN2的氨基酸序列。由于缺乏关于绵羊钙蛋白酶的结构信息，因此基于人钙蛋白酶1（h-CAPN1）X射线晶体结构（o-CAPN1和o-CAPN2）的活性位点裂开了计算机同源模型（PDB代码） 1ZCM）。这些模型用于合理化所观察到的化合物4-13的SAR和观察到的9的选择性。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210087186A1

  公开（公告）日：2021-03-25

  The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.

  本发明提供一种具有降低葡糖鞘脂的作用（例如促进葡糖鞘脂代谢、抑制葡糖鞘脂合成、促进葡糖鞘脂分解等）的化合物，预计可用作预防或治疗溶酶体疾病（例如高雪氏病）、神经退行性疾病（例如帕金森病、路易体痴呆症、多系统萎缩症）等的药剂。本发明涉及一种由式（I）表示的化合物 其中每个符号如说明书中所述，或其盐。